Skip to main content
. Author manuscript; available in PMC: 2015 Oct 29.
Published in final edited form as: Sci Transl Med. 2015 Apr 29;7(285):285ra63. doi: 10.1126/scitranslmed.aaa2546

Figure 5. CB-derived T-cells for clinical use.

Figure 5

(A) Phenotype of three CB-derived T-cell lines manufactured from the 20% fraction of a clinical CB unit. (B) Reactivity of the CB line infused in to patient P3275 to viral antigens and epitopes of pp65 including the typical epitope NLV and the atypical epitope LQT. The response to LQT was also confirmed by pentamer analysis. (D) CMV load of P2891 (left) in relation to the number of reactive cells from the peripheral blood (right). The timing of T-cell infusions is indicated by arrows.